Nasobec, nasal spray 50 µg/dose, 200 doses

Composition

Active ingredient:  

Beclomethasone dipropionate 50 mcg;

Auxiliary substances:  

benzalkonium chloride;

phenylethanol;

polysorbate 80;

dextrose anhydride;

MCC;

sodium carboxymethylcellulose; 

hydrochloric acid; 

purified water.

Pharmacological action

Nasobek – decongestant local, anti-inflammatory local, anti-allergic.

Pharmacodynamics

Beclomethasone dipropionate-a synthetic corticosteroid for topical use-has anti-inflammatory, anti-allergic and immunosuppressive effects. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, inhibits the release of arachidonic acid.

Prevents marginal accumulation of neutrophils, reduces inflammatory exudation and lymphokine production, inhibits macrophage migration, reduces the intensity of infiltration and granulation processes, and the formation of chemotaxis substance.

Reduces swelling of the nasal mucosa, mucus production. Improves mucociliary transport. It is well tolerated during long-term treatment, does not have mineralocorticoid activity, and practically does not have a resorptive effect.

The therapeutic effect of Nasobek, unlike local vasoconstrictors for the treatment of rhinitis, is not immediately apparent with intranasal use. Relief of rhinitis symptoms usually becomes noticeable within a few days of starting treatment.

Pharmacokinetics

With the inhaled method of use in the recommended doses, it does not have significant systemic activity. After intranasal use, it is rapidly absorbed in the nasal mucosa. Part of the administered drug is swallowed. Most of the drug that enters the gastrointestinal tract is inactivated when it first passes through the liver.

Absorption from the gastrointestinal tract is low. T_1/2 — 15 h. Binding to plasma proteins is 87%.

The main part of the drug (35-76%), regardless of the method of use, is excreted within 96 hours with feces, mainly in the form of polar metabolites,10-15% – by the kidneys.

Indications

• Rhinitis.
• Bronchial asthma.
• Allergic rhinitis.

Use during pregnancy and lactation

It is allowed only if the expected benefit to the mother exceeds the possible risk to the fetus. When treating Nasobek during breastfeeding, care should be taken.

Contraindications

• hypersensitivity to the components of the drug;
• hemorrhagic diathesis;
• frequent nosebleeds;
• respiratory tuberculosis;
• children under 6 years of age;
• pregnancy (I trimester);
• viral and fungal diseases.

With caution:  amoebiasis, glaucoma, severe liver failure, hypothyroidism, recent myocardial infarction, ulceration of the nasal septum, recent surgery in the nasal cavity, recent nasal trauma, pregnancy (II-III trimester), lactation.

Side effects

When used in therapeutic doses, they are rare.

From the respiratory system: sneezing, irritation, burning and dryness of the nasal mucosa and nasopharyngeal infections caused by fungal flora, rhinorrhea; in rare cases-nosebleeds, atrophy of the nasal mucosa, cough; extremely rare — perforation of the nasal septum.

Allergic reactions: rash, urticaria, angioedema, conjunctival hyperemia.

Others: headache, increased intraocular pressure, myalgia, drowsiness, decreased taste sensations.

With prolonged use in doses of more than 1500 mcg/day — systemic effects (including adrenal insufficiency).

Interaction

When used together, phenobarbital, phenytoin, and rifampicin reduce the effectiveness of Beclomethasone (induction of microsomal oxidation enzymes).

When used together, methandrostenolone, estrogens, beta-2-adrenostimulants, theophylline, corticosteroids for oral use enhance the effect of Beclomethasone.

When used together, Nasobek increases the effect of beta-adrenostimulants.

How to take, course of use and dosage

Nasobek is used intranasally.

Release the nasal passages before use.

Adults and children over 6 years of age: 1 dose (50 mcg) in each nasal passage 2-4 times a day (200-400 mcg).

Then the dose is reduced depending on the patient’s reaction.

Overdose

With long-term use in high doses, as well as with the simultaneous use of other (systemic) drugs. CORTICOSTEROIDS may cause symptoms of hypercorticism. In this case, the use of the drug should be discontinued, gradually reducing the dose.

Special instructions

It is necessary to protect the eyes from ingestion of the drug.

Instructions for proper use of Nasobek spray:

Before applying the spray for the first time, remove the plastic strip between the bubble cap and the nasal applicator.

1. Before applying, shake the bottle slightly and then remove the cap of the nasal applicator. 2. Hold the bubble between your thumb and index finger so that the bottom of the bubble rests on your thumb, and your index and middle fingers rest on either opposite side of the bottom of the applicator. 3. Before the first use of the drug or in the case of a one-week break in use, the first dose should be released into a free space. 4. Exhale lightly through your nose. 5. The nostril that will not be injected with the drug should be pinched with your finger, and the end part of the applicator should be inserted into the free nostril. Then tilt your head slightly so that the bubble is in a perpendicular position. 6. After that, inhale lightly through the open nostril and simultaneously press the nasal applicator and administer the dose. 7. Exhale through your mouth. 8. If Nasobek is re-injected into the same nostril, repeat the operations described in paragraphs 7 and 8.9. If the drug is re-injected into another nostril, repeat the operations described in paragraphs 6,7,8 and 9.

After finishing the application of the drug, clean the end of the applicator with a clean cloth and return the cap to its place. Cleaning the nasal applicator

The nasal applicator should be cleaned at least once a week to prevent it from becoming clogged.

To do this, lightly press the bottom of the bubble and remove the nasal applicator from the bubble. The applicator and cap are washed with warm water and allowed to dry. After that, the applicator and cap are put back on the bottle.

Form of production

Nasal spray

Storage conditions

In a dark place, at a temperature of 10-25 °C

Shelf life

4 years

Active ingredient

Beclomethasone

Conditions of release from pharmacies

By prescription

Dosage form

nasal spray

Description

Nursing mothers as prescribed by a doctor, Pregnant women in the second and third trimester as prescribed by a doctor, Children as prescribed by a doctor, Children over 6 years of age, Adults as prescribed by a doctor

Indications

Runny Nose, Allergy, Pollinosis, Allergic Rhinitis